KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBIT Margin (2017 - 2025)

Amneal Pharmaceuticals has reported EBIT Margin over the past 9 years, most recently at 13.76% for Q4 2025.

  • Quarterly results put EBIT Margin at 13.76% for Q4 2025, up 338.0% from a year ago — trailing twelve months through Dec 2025 was 13.05% (up 413.0% YoY), and the annual figure for FY2025 was 13.05%, up 413.0%.
  • EBIT Margin for Q4 2025 was 13.76% at Amneal Pharmaceuticals, up from 8.97% in the prior quarter.
  • Over the last five years, EBIT Margin for AMRX hit a ceiling of 15.37% in Q2 2025 and a floor of 35.51% in Q2 2022.
  • Median EBIT Margin over the past 5 years was 9.14% (2021), compared with a mean of 6.71%.
  • Biggest five-year swings in EBIT Margin: crashed -4805bps in 2022 and later surged 4888bps in 2023.
  • Amneal Pharmaceuticals' EBIT Margin stood at 2.08% in 2021, then surged by 184bps to 5.91% in 2022, then tumbled by -61bps to 2.3% in 2023, then skyrocketed by 351bps to 10.38% in 2024, then surged by 33bps to 13.76% in 2025.
  • The last three reported values for EBIT Margin were 13.76% (Q4 2025), 8.97% (Q3 2025), and 15.37% (Q2 2025) per Business Quant data.